A pharmaceutical-grade soluble yeast beta-(1,3)(1,6)-glucan was tested with human neutrophils and monocytes. Binding increased with concentration and depended on serum, time, temperature, complement component C3, and the CD11b/CD18 chains of complement receptor 3. Detection of iC3b supported complement-mediated opsonization. This ex-vivo receptor-binding study does not establish a clinical immune benefit and does not directly test Aureobasidium glucan.
Soluble yeast glucan binding to human neutrophils and monocytes was characterized.
Binding depended on complement and CR3, with iC3b detected on glucan-bound cells.
Receptor binding ex vivo does not establish clinical benefit.
AI-generated summary for accessibility. Always refer to the original paper.
Bose, Nandita; Chan, Anissa S. H.; Guerrero, Faimola; Maristany, Carolyn M.; Qiu, Xiaohong; Walsh, Richard M.; Ertelt, Kathleen E.; Jonas, Adria Bykowski; Gorden, Keith B.; Dudney, Christine M.; Wurst, Lindsay R.; Danielson, Michael E.; Elmasry, Natalie; Magee, Andrew S.; Patchen, Myra L.; Vasilakos, John P.. Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent. Frontiers in Immunology. 2013. DOI: 10.3389/fimmu.2013.00230.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.